Cannabis list as “high-risk” product in new congressional bill; Anti-drug group pushes hemp recriminalization; DEA vs. FDA on psychedelics
Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day.
Your support makes Marijuana Moment possible…
Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there.
Support our work at https://www.patreon.com/marijuanamoment
/ TOP THINGS TO KNOW
A new Government Accountability Office report concluded that federal agencies’ policies that govern the drug scheduling process have “gaps” that “may pose a risk”—a finding that comes as the Drug Enforcement Administration is considering broadly rescheduling marijuana.
“DEA does not have any policies or procedures regarding how its staff are to conduct evaluations or schedule substances.”
Rep. Valerie Foushee (D-NC) and Del. James Moylan (R-Guam) filed a bill aimed at protecting consumers from online scams that includes a provision designating cannabis as a “high-risk” product that would require companies advertising it to undergo
Read full article on Marijuana Moment
